Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

NCT02135042 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT02135042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02135042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Lead sponsor
NRG Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
July 1, 2014
Completion date
January 1, 2034
Enrollment
924 (estimated)
Sites
213

Conditions

As the registry lists them; a condition with its own page is linked.

ebv infection, stage ii nasopharyngeal carcinoma ajcc v7, stage iii nasopharyngeal carcinoma ajcc v7, stage iva nasopharyngeal carcinoma ajcc v7, stage ivb nasopharyngeal carcinoma ajcc v7